30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Elizabeth Hougen

Track

Insider profile

Performance

Overall performance
3.6
Performance over holding periods
3.6
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 64% 68% 82%
Transactions
12 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Senior Vice President - Finance Akcea Therapeutics Inc Aug. 31, 2017 - Dec. 31, 2018
Chief Financial Officer Akcea Therapeutics Inc Jan. 1, 2015 - Aug. 31, 2017
Elizabeth Hougen's trades of Ionis Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-18 2026-03-17
PlS Planned sale
25,769 -15.8%
139.37
US$596,729 		25,769 -15.8% 139.37 US$596,729
2026-03-18 2026-03-16
PlS Planned sale
24,412 +3.6%
249.16
US$4,023,659 		24,412 +3.6% 249.16 US$4,023,659
2026-03-18 2026-03-16
PlS Planned sale
42,691 -10.3%
220.39
US$4,374,142 		42,691 -10.3% 220.39 US$4,374,142
2026-03-16 2026-03-16
PrS Proposed sale
225,200
72.31
US$16,284,212 		225,200 72.31 US$16,284,212
2026-02-02 2026-01-30
S Sale
6,988 -5.0%
83.24
US$581,702 		6,988 -5.0% 83.24 US$581,702
2026-01-30 2026-01-30
PrS Proposed sale
6,988
83.01
US$580,049 		6,988 83.01 US$580,049
2026-01-20 2026-01-16
S Sale
12,922 -9.3%
75.22
US$971,993 		12,922 -9.3% 75.22 US$971,993
2026-01-16 2026-01-16
PrS Proposed sale
12,922
76.24
US$985,109 		12,922 76.24 US$985,109
2025-10-01 2025-09-30
PlS Planned sale
49,800 -31.1%
65.26
US$3,249,734 		49,800 -31.1% 65.26 US$3,249,734
2025-02-03 2025-01-31
S Sale
1,523 -1.4%
32.44
US$49,404 		1,523 -1.4% 32.44 US$49,404
2025-01-31 2025-01-31
PrS Proposed sale
2,069
35.00
US$72,415 		2,069 35.00 US$72,415
2025-01-17 2025-01-16
S Sale
8,870 -7.6%
32.81
US$290,989 		8,870 -7.6% 32.81 US$290,989
2025-01-16 2025-01-16
PrS Proposed sale
8,870
32.70
US$290,049 		8,870 32.70 US$290,049
2024-09-04 2024-02-02
PrS Proposed sale
2,162
49.54
US$107,105 		2,162 49.54 US$107,105
2024-02-02 2024-02-02
PrS Proposed sale
2,125
49.54
US$105,272 		2,125 49.54 US$105,272
2024-02-02 2024-02-02
S Sale
2,125 -2.2%
49.54
US$105,272 		2,125 -2.2% 49.54 US$105,272
2024-01-18 2024-01-17
S Sale
8,683 -8.7%
50.42
US$437,771 		8,683 -8.7% 50.42 US$437,771
2024-01-17 2024-01-17
PrS Proposed sale
8,683
50.54
US$438,834 		8,683 50.54 US$438,834
2023-02-07 2023-02-06
PrS Proposed sale
2,079
40.69
US$84,598 		2,079 40.69 US$84,598
2023-02-07 2023-02-06
S Sale
2,079 -2.7%
40.59
US$84,392 		2,079 -2.7% 40.59 US$84,392
2023-01-19 2023-01-18
S Sale
8,280 -10.1%
39.70
US$328,721 		8,280 -10.1% 39.70 US$328,721
2020-11-30 2020-11-25
PlS Planned sale
21,680 -40.0%
50.05
US$1,085,084 		21,680 -40.0% 50.05 US$1,085,084
2020-11-25 2020-11-24
PlS Planned sale
4,320 -11.7%
50.83
US$219,586 		4,320 -11.7% 50.83 US$219,586
2020-11-25 2020-11-23
PlS Planned sale
5,875 -15.3%
50.11
US$294,396 		5,875 -15.3% 50.11 US$294,396
2020-11-25 2020-11-23
PlS Planned sale
13,125 -28.8%
50.11
US$657,694 		13,125 -28.8% 50.11 US$657,694
2018-01-17 2018-01-16
S Sale
2,724 -15.8%
51.76
US$140,994 		2,724 -15.8% 51.76 US$140,994
2017-01-18 2017-01-17
S Sale
623 -5.7%
46.29
US$28,839 		623 -5.7% 46.29 US$28,839
2017-01-18 2017-01-17
S Sale
539 -5.5%
46.29
US$24,951 		539 -5.5% 46.29 US$24,951
2017-01-18 2017-01-17
S Sale
733 -8.0%
46.29
US$33,931 		733 -8.0% 46.29 US$33,931